Healthcare Industry News: shock wave technology
News Release - July 27, 2011
Tissue Regeneration Technologies, LLC Announces Release of CPT Codes for ESWT in Wound HealingWOODSTOCK, Ga.--(Healthcare Sales & Marketing Network)-- Tissue Regeneration Technologies, LLC (TRT), a regenerative medicine company owning proprietary SoftWave™ unfocused shockwave therapy technology for use in cost-effective noninvasive wound management, announces that the American Medical Association (AMA) has released two Current Procedural Terminology (CPT) Category III codes for Extracorporeal shock wave technology (ESWT) in wound healing: 0299T and 0300T.
In 2009, TRT petitioned the AMA for purposes of establishing a Category III Code for the use of shockwave and pressure pulse technology in the treatment of wounds. Studies show that TRT's SoftWave technology emits pain-free therapeutic pressure pulses, or shockwaves, leading to the production of growth factors and inflammatory mediators critical in wound management. Early clinical data from international trials shows that the use of SoftWave technology leads to more rapid closure and repair of wounds on organs, including the skin and heart, and may be useful as a stand alone or supplemental approach to wound care that will improve patient outcomes.
"The establishment of CPT Category III codes for wound care is a benefit to patients and to the health system which will soon be offering emerging wound management technology that is substantially lower in cost and therapy time than the current standard of care. SoftWave technology will be a major contributor towards health savings in the United States," said John Warlick, President and CEO of TRT. "This has been our objective since we first entered the shockwave industry. Our patented unfocused SoftWave technology has the potential to become the new standard of care in wound management."
The company is currently involved in U.S. Food and Drug Administration trials for its “Gold” product line, which is approved in Europe, Asia, Canada and South America. TRT is confident its technologies will dramatically improve patient care and reduce health care costs.
About Tissue Regeneration Technologies, LLC
TRT is an international medical device company established to develop, manufacture and sell SoftWave™ acoustical pressure pulse devices to treat various conditions poorly served by the current standard of care. TRT is headquartered in Woodstock, Georgia. TRT is currently conducting an FDA trial with its DermaGold™ device for the treatment of wounds. TRT has FDA clearance to market its LithoGold™ lithotripsy system for treatment of kidney and ureteral stones. TRT devices are CE approved and distributed in approximately 20 countries worldwide. For more information, please visit the company’s website at www.trtllc.com.
Notice: This press release contains forward-looking statements within the meaning of the federal security laws. Forward-looking statements are only predictions and not guarantees of performance. You should not place undue reliance on any forward-looking statements. TRT’s SoftWave technology is undergoing investigational use in the United States and is not currently available for sale.
Source: Tissue Regeneration Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.